JP2017513502A5 - - Google Patents

Download PDF

Info

Publication number
JP2017513502A5
JP2017513502A5 JP2016564032A JP2016564032A JP2017513502A5 JP 2017513502 A5 JP2017513502 A5 JP 2017513502A5 JP 2016564032 A JP2016564032 A JP 2016564032A JP 2016564032 A JP2016564032 A JP 2016564032A JP 2017513502 A5 JP2017513502 A5 JP 2017513502A5
Authority
JP
Japan
Prior art keywords
composition
recombinant
recombinant listeria
prfa
listeria strain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016564032A
Other languages
English (en)
Japanese (ja)
Other versions
JP7009061B2 (ja
JP2017513502A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/025690 external-priority patent/WO2015164121A1/en
Publication of JP2017513502A publication Critical patent/JP2017513502A/ja
Publication of JP2017513502A5 publication Critical patent/JP2017513502A5/ja
Application granted granted Critical
Publication of JP7009061B2 publication Critical patent/JP7009061B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016564032A 2014-04-24 2015-04-14 組み換え型リステリアワクチン株およびこれを生産する方法 Expired - Fee Related JP7009061B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461983732P 2014-04-24 2014-04-24
US61/983,732 2014-04-24
PCT/US2015/025690 WO2015164121A1 (en) 2014-04-24 2015-04-14 Recombinant listeria vaccine strains and methods of producing the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020047632A Division JP2020099352A (ja) 2014-04-24 2020-03-18 組み換え型リステリアワクチン株およびこれを生産する方法

Publications (3)

Publication Number Publication Date
JP2017513502A JP2017513502A (ja) 2017-06-01
JP2017513502A5 true JP2017513502A5 (enExample) 2018-05-31
JP7009061B2 JP7009061B2 (ja) 2022-01-25

Family

ID=54333010

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016564032A Expired - Fee Related JP7009061B2 (ja) 2014-04-24 2015-04-14 組み換え型リステリアワクチン株およびこれを生産する方法
JP2020047632A Withdrawn JP2020099352A (ja) 2014-04-24 2020-03-18 組み換え型リステリアワクチン株およびこれを生産する方法
JP2022087587A Active JP7300041B2 (ja) 2014-04-24 2022-05-30 組み換え型リステリアワクチン株およびこれを生産する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020047632A Withdrawn JP2020099352A (ja) 2014-04-24 2020-03-18 組み換え型リステリアワクチン株およびこれを生産する方法
JP2022087587A Active JP7300041B2 (ja) 2014-04-24 2022-05-30 組み換え型リステリアワクチン株およびこれを生産する方法

Country Status (15)

Country Link
US (2) US10258679B2 (enExample)
EP (1) EP3134510B1 (enExample)
JP (3) JP7009061B2 (enExample)
KR (2) KR102359691B1 (enExample)
CN (1) CN106459887A (enExample)
AU (1) AU2015250111A1 (enExample)
BR (1) BR112016024352A2 (enExample)
CA (1) CA2946716A1 (enExample)
IL (1) IL248483A0 (enExample)
MA (1) MA39849A (enExample)
MX (1) MX2016013985A (enExample)
RU (1) RU2016145464A (enExample)
SG (2) SG10202011841WA (enExample)
TW (2) TWI722858B (enExample)
WO (1) WO2015164121A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
AU2012229218B2 (en) 2011-03-11 2017-03-02 Advaxis, Inc. Listeria-based adjuvants
WO2013138337A1 (en) 2012-03-12 2013-09-19 Advaxis Suppressor cell function inhibition following listeria vaccine treatment
KR20160130774A (ko) 2014-02-18 2016-11-14 어드박시스, 인크. 바이오마커 지도된 다중-표적 면역치료
SG10202011841WA (en) 2014-04-24 2021-01-28 Advaxis Inc Recombinant listeria vaccine strains and methods of producing the same
JP2017536095A (ja) * 2014-10-14 2017-12-07 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 組み換え型リステリアワクチン株および癌免疫療法におけるその使用方法
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
KR102883915B1 (ko) 2015-12-16 2025-11-18 시애틀 프로젝트 코포레이션 신생항원 동정, 제조, 및 용도
CA3035591A1 (en) 2016-11-30 2018-06-07 Advaxis, Inc. Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
CN106978381A (zh) * 2017-03-23 2017-07-25 上海理工大学 prfA基因缺失单核细胞增生李斯特氏菌及制备方法
SG11202002157TA (en) 2017-09-19 2020-04-29 Advaxis Inc Compositions and methods for lyophilization of bacteria or listeria strains
JP7227237B2 (ja) 2017-10-10 2023-02-21 グリットストーン バイオ インコーポレイテッド ホットスポットを利用した新生抗原の特定
EP3703734A1 (en) 2017-10-31 2020-09-09 Pantarhei Bioscience B.V. Immunotherapeutic methods for treating and/or preventing lung cancer
US11885815B2 (en) 2017-11-22 2024-01-30 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
AU2019231783B2 (en) * 2018-03-09 2023-11-16 Advaxis, Inc. Compositions and methods for evaluating attenuation and infectivity of Listeria strains
CN110408634B (zh) * 2018-04-27 2021-08-03 苏州若泰医药科技有限公司 一种非整合李斯特菌疫苗及抗肿瘤免疫应答方法
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
WO2021259963A1 (en) 2020-06-23 2021-12-30 Pandora Endocrine Innovation B.V. Immunization against wnt4 for treatment and prophylaxis of breast cancer
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
CN118900696A (zh) 2021-10-19 2024-11-05 科学医疗有限责任公司 雄性避孕
CN116218754B (zh) * 2023-04-10 2025-06-03 四川大学 一种提高绵羊李斯特菌膜囊泡产量的方法及应用
CN119060155B (zh) * 2024-11-07 2025-03-07 山东大学 一种蛋白在调节肠道稳态及抵抗致病菌感染中的应用

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830702A (en) 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
US7662396B2 (en) 2001-03-26 2010-02-16 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US20070264279A1 (en) * 1994-11-08 2007-11-15 Claudia Gravekamp Compositions and methods comprising a MAGE-b antigen
US8956621B2 (en) 1994-11-08 2015-02-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical dysplasia
US6051237A (en) 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
US8114414B2 (en) 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
US7820180B2 (en) 2004-09-24 2010-10-26 The Trustees Of The University Of Pennsylvania Listeria-based and LLO-based vaccines
US7794729B2 (en) * 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
US6099848A (en) 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
US6855320B2 (en) 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
JP2004500405A (ja) 2000-03-29 2004-01-08 ザ トラスティーズ オブ ザ ユニバーシティー オブ ペンシルヴァニア 抗原の免疫原性を増強するための組成物および方法
US7700344B2 (en) 2001-03-26 2010-04-20 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
JP2005527240A (ja) 2002-05-29 2005-09-15 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 弱毒リステリア種とこれを使用する方法
AU2004204751A1 (en) 2003-01-09 2004-07-29 The Trustees Of The University Of Pennsylvania Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector
US7855064B2 (en) 2004-08-13 2010-12-21 The Trustees Of The University Of Pennsylvania Antibiotic resistance free vaccines and methods for constructing and using same
AU2005271246A1 (en) * 2004-08-13 2006-02-16 The Trustees Of The University Of Pennsylvania Methods for constructing antibiotic resistance free vaccines
US7858097B2 (en) * 2004-08-13 2010-12-28 The Trustees Of The University Of Pennsylvania Antibiotic resistance free Listeria strains and methods for constructing and using same
CA2584130A1 (en) * 2004-10-18 2006-04-27 Medimmune, Inc. High cell density process for growth of listeria
US7935804B2 (en) 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
US8268326B2 (en) 2006-08-15 2012-09-18 The Trustees Of The University Of Pennsylvania Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
EP2977456B1 (en) 2006-08-15 2017-10-25 The Trustees Of The University Of Pennsylvania Compositions comprising hmw-maa and fragments thereof for treating cancer
WO2008130551A2 (en) 2007-04-16 2008-10-30 The Trustees Of The University Of Pennsylvania Antibiotic resistance free listeria strains and methods for constructing and using same
US20140234370A1 (en) 2009-11-11 2014-08-21 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
EP2853269B1 (en) 2008-05-19 2019-05-01 Advaxis, Inc. Dual delivery system for heterologous antigens comprising a recombinant Listeria strain attenuated by mutation of dal/dat and deletion of ActA comprising a nucleic acid molecule encoding an listeriolysin O - prostate specific anigen fusion protein
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
CN102076843A (zh) * 2008-05-19 2011-05-25 艾杜罗生物科技公司 包含prfa*突变体李斯特菌的组合物及其使用方法
US20120135033A1 (en) 2008-05-19 2012-05-31 Anu Wallecha Multiple delivery system for heterologous antigens
US20150366955A9 (en) 2009-11-11 2015-12-24 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US20120100170A1 (en) * 2008-07-24 2012-04-26 Lauer Peter M Compositions and methods for the treatment of hepatitis c
EP2403935B1 (en) 2009-03-04 2017-05-10 The Trustees Of The University Of Pennsylvania Compositions comprising angiogenic factors and methods of use thereof
WO2011060260A2 (en) 2009-11-11 2011-05-19 Advaxis Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
US20110223187A1 (en) 2010-02-15 2011-09-15 Vafa Shahabi Live listeria-based vaccines for central nervous system therapy
US20110305724A1 (en) 2010-04-19 2011-12-15 Yvonne Paterson Immunotherapeutic, anti-tumorigenic compositions and methods of use thereof
EP2621527A4 (en) 2010-10-01 2015-12-09 Univ Pennsylvania USE OF LISTERIA VACCINE VECTORS TO REVERSE VACCINE IMMUNITY IN PATIENTS WITH PARASITIC INFECTIONS
DK2640842T3 (en) 2010-11-17 2018-08-13 Aduro Biotech Inc Methods and compositions for inducing an immune response to EGFRVIII
AU2012229218B2 (en) 2011-03-11 2017-03-02 Advaxis, Inc. Listeria-based adjuvants
WO2013138337A1 (en) 2012-03-12 2013-09-19 Advaxis Suppressor cell function inhibition following listeria vaccine treatment
KR20160130774A (ko) 2014-02-18 2016-11-14 어드박시스, 인크. 바이오마커 지도된 다중-표적 면역치료
RU2016137834A (ru) 2014-02-25 2018-03-29 Адваксис, Инк. КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ ОПУХОЛЕЙ, СВЕРХЭКСПРЕССИРУЮЩИХ HER2/neu
BR112016020364A2 (pt) 2014-03-05 2018-01-16 Advaxis, Inc. métodos para suscitar uma resposta de uma célula t antitumoral em um indivíduo tendo um tumor ou câncer e para aumentar a razão de células t efetoras sobre células t reguladoras no baço de um indivíduo
SG10202011841WA (en) 2014-04-24 2021-01-28 Advaxis Inc Recombinant listeria vaccine strains and methods of producing the same
CN106794234A (zh) 2014-05-02 2017-05-31 宾夕法尼亚大学理事会 用于治疗her‑2阳性癌症的联合免疫疗法和放疗
WO2016011320A1 (en) 2014-07-18 2016-01-21 Advaxis, Inc. Bivalent listeria-based delivery system of heterologous antigens
SG11201700092XA (en) 2014-07-18 2017-02-27 Advaxis Inc Recombinant listeria strain expressing heterologous antigen fusion proteins and methods of use thereof
EP3193921A4 (en) 2014-07-18 2018-04-25 Advaxis, Inc. Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer
AU2015289449A1 (en) 2014-07-18 2017-02-09 Advaxis, Inc. Listeria-based immunogenic compositions for eliciting anti-tumor responses
JP2017536095A (ja) 2014-10-14 2017-12-07 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 組み換え型リステリアワクチン株および癌免疫療法におけるその使用方法
MA41218A (fr) 2014-12-19 2017-10-24 Advaxis Inc Combinaison de vaccin à base de listeria comportant des anticorps anti-ox40 ou anti-gitr
US20160220652A1 (en) 2015-02-03 2016-08-04 Advaxis, Inc. Methods of using recombinant listeria vaccine strains in disease immunotherapy
WO2016126878A2 (en) 2015-02-03 2016-08-11 The Trustees Of The University Of Pennsylvania Listeria-based immunomodulation
WO2016126876A2 (en) 2015-02-03 2016-08-11 Advaxis, Inc. Listeria-based adjuvants
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
WO2016154412A2 (en) 2015-03-26 2016-09-29 The Trustees Of The University Of Pennsylvania Combination of a pd-1 antagonist and a listeria based vaccine for treating pancreatic cancer
US20180104284A1 (en) 2015-05-13 2018-04-19 Advaxis, Inc. Immunogenic Listeria-Based Compositions Comprising Truncated Acta-Antigen Fusions And Methods Of Use Thereof
US20190381160A1 (en) 2015-05-26 2019-12-19 Advaxis, Inc. Personalized delivery vector-based immunotherapy and uses thereof
US20170204361A1 (en) 2015-06-24 2017-07-20 Advaxis, Inc. Manufacturing device and process for personalized delivery vector-based immunotherapy
MA42841A (fr) 2015-09-15 2018-07-25 Advaxis Inc Procédé de fabrication d'une formulation immunothérapeutique comprenant une souche de listeria de recombinaison
WO2017048850A1 (en) 2015-09-15 2017-03-23 Advaxis, Inc. Listeria-based immunogenic compositions and methods of use thereof in cancer prevention and treatment
CA2998889A1 (en) 2015-09-17 2017-03-23 Advaxis, Inc. Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy
MA43124A (fr) 2015-10-14 2018-09-05 Advaxis Inc Souches recombinées vaccinales de listeria et leurs méthodes d'utilisation en immunothérapie anticancéreuse
WO2017085691A1 (en) 2015-11-20 2017-05-26 Advaxis, Inc. Manufacturing device and method of an immunotherapeutic formulation comprising a recombinant listeria strain
WO2017106754A2 (en) 2015-12-16 2017-06-22 Advaxis, Inc. Listeria-based immunotherapy and methods of use thereof
MX2018009225A (es) 2016-01-27 2019-08-21 Advaxis Inc Inmunoterapia basada en vectores de distribución personalizados y usos de la misma.
CA3029235A1 (en) 2016-07-05 2018-01-11 Advaxis, Inc. Listeria-based immunogenic compositions comprising wilms tumor protein antigens and methods of use thereof
MA46721A (fr) 2016-11-07 2019-09-11 Advaxis Inc Combinaison d'un vaccin à base de listeria avec des anticorps anti-ctla-4 ou anti-cd137
WO2018102585A1 (en) 2016-11-30 2018-06-07 Advaxis, Inc. Personalized immunotherapy in combination with immunotherapy targeting recurrent cancer mutations
CA3035591A1 (en) 2016-11-30 2018-06-07 Advaxis, Inc. Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
TW201833323A (zh) 2017-01-05 2018-09-16 美商艾法西斯公司 重組李斯特菌屬疫苗菌株及在癌症免疫治療中使用該菌株之方法

Similar Documents

Publication Publication Date Title
JP2017513502A5 (enExample)
RU2016145464A (ru) Рекомбинантные вакцинные штаммы listeria и способы их получения
AU2017297610B2 (en) Compositions and methods for alphavirus vaccination
Lazzaro et al. CD 8 T‐cell priming upon mRNA vaccination is restricted to bone‐marrow‐derived antigen‐presenting cells and may involve antigen transfer from myocytes
CN107434827B (zh) 用作诱导抗原特异性t细胞反应的免疫原性增强剂的融合蛋白
CN109843323B (zh) 用于黄病毒疫苗接种的组合物和方法
JP2017195888A5 (enExample)
JP2006501825A5 (enExample)
JP2017511135A5 (enExample)
JP2016503655A5 (enExample)
JP2009540801A5 (enExample)
JP2017507943A5 (enExample)
MX2020000221A (es) Secuencias de aminoacidos y de acidos nucleicos de adenovirus de grandes simios no humanos, vectores que contienen las mismas y usos de las mismas.
JP2020528911A5 (enExample)
WO2014205579A4 (en) Modified matrix proteins of vesicular stomatitis virus
JP2019508403A5 (enExample)
AU2017264901A1 (en) Combination prime: boost therapy
MX2019000215A (es) Composiciones inmunogenicas a base de listeria que comprenden antigenos de proteinas del tumor de wilms y metodos para su uso.
US20210284713A1 (en) Anti covid-19 therapies using cd40 ligand fusion protein
JP2012516140A5 (enExample)
JP2019505567A5 (enExample)
CN104662152B (zh) 包含异源多肽的基于cyaa的嵌合蛋白及其在诱导免疫应答中的应用
CN102178950B (zh) 一种亚单位疫苗免疫佐剂及应用
Shcherbinin et al. Protective immune response against Bacillus anthracis induced by intranasal introduction of a recombinant adenovirus expressing the protective antigen fused to the Fc-fragment of IgG2a
Yazdanian et al. Evaluation of cellular responses for a chimeric HBsAg-HCV core DNA vaccine in BALB/c mice